Effect of Health Care Reform and ACOs on Disease Management

Share Article

Health Industries Research Companies (HIRC) Research with Managed Care Executives Examines Implications of Current Disease Management Trends for Pharmaceutical Firms

Health Industries Research Companies (HIRC) believes health care reform is an opportunity for pharmaceutical manufacturers to capitalize on higher health plan demand for disease management (DM). HIRC’s spring research with leading managed care executives discovers that the vast majority of panelists surveyed envision disease management program offerings increasing or staying the same in the future. “At HIRC we believe this represents an opportunity for manufacturers to step up to the plate and offer appropriately targeted DM programs, and in doing so, improve relations with health plans,” explains Karen Ernst, HIRC’s Disease Management Research Director. HIRC also finds that several large leading pharmaceutical manufacturers are best positioned to assist health plans in their disease management efforts. Pfizer, GlaxoSmithKline and Merck are noted most often as the manufacturers that provide the disease management programs of greatest quality and value. http://www.hirc.com/highlights

HIRC research finds that Medicare executives remain uncertain, but optimistic about the benefits of accountable care organizations (ACOs). HIRC also queried Medicare executives representing almost 50 million lives on whether ACOs will lead to greater cost savings in the face of an evolving regulatory environment. HIRC research reveals that in spite of recent publicity surrounding ACOs, nearly 50% of Medicare executives are unsure whether these new organizations will actually save money. “Organizations are interpreting the recent ACO regulations issued by CMS and their potential impact,” Karen Ernst says. “Once these regulations have been finalized, we will have a much clearer picture of which organizations will form ACOs.” While uncertainty surrounding ACO development exists, nearly one-third (30%) of respondents are optimistic that accountability will lead to better results and outcomes while simultaneously lowering costs. Additionally, HIRC research explores the changing role of disease management programs within ACOs. http://www.hirc.com/highlights

Health Industries Research Companies’ Health & Disease Management Service is an ongoing research project that focuses on health and disease management initiatives within significant managed care customer segments. In January 2011, HIRC surveyed 111 panelists from four managed care markets (including 33 Medicare executives) and conducted one-on-one follow-up interviews with a subset of 48 respondents to gather ratings and qualitative information.

HIRC’s Health & Disease Management research is now available online to subscribers at HIRC’s website at http://www.hirc.com/hdm/summary

HEALTH INDUSTRIES RESEARCH COMPANIES (HIRC) is an independent, nonpartisan organization that conducts strategic market research on trends in health care, pharmaceutical, and managed care businesses. HIRC’s benchmark studies focus on the marketing needs of pharmaceutical companies by providing research critical to the development of successful customer-focused marketing strategies. http://www.hirc.com


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Amy Hanley

(831) 426-5283 x29
Email >
Visit website